136 related articles for article (PubMed ID: 22239432)
1. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith R; You Z; Alvarez R; Partridge E; Grizzle W; LoBuglio A
Cancer Biother Radiopharm; 2012 Feb; 27(1):36-40. PubMed ID: 22239432
[TBL] [Abstract][Full Text] [Related]
2. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?
Grana C; Bartolomei M; Handkiewicz D; Rocca P; Bodei L; Colombo N; Chinol M; Mangioni C; Malavasi F; Paganelli G
Gynecol Oncol; 2004 Jun; 93(3):691-8. PubMed ID: 15196866
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
Meredith RF; Alvarez RD; Partridge EE; Khazaeli MB; Lin CY; Macey DJ; Austin JM; Kilgore LC; Grizzle WE; Schlom J; LoBuglio AF
Cancer Biother Radiopharm; 2001 Aug; 16(4):305-15. PubMed ID: 11603001
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
Shen S; Forero A; Meredith RF; LoBuglio AF
Cancer Biother Radiopharm; 2011 Feb; 26(1):127-33. PubMed ID: 21355784
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.
Koi L; Bergmann R; Brüchner K; Pietzsch J; Pietzsch HJ; Krause M; Steinbach J; Zips D; Baumann M
Radiother Oncol; 2014 Feb; 110(2):362-9. PubMed ID: 24440046
[TBL] [Abstract][Full Text] [Related]
9. Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody.
Hanaoka H; Kuroki M; Yamaguchi A; Achmad A; Iida Y; Higuchi T; Oriuchi N; Tsushima Y; Endo K
Cancer Biother Radiopharm; 2014 Mar; 29(2):70-6. PubMed ID: 24299067
[TBL] [Abstract][Full Text] [Related]
10. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
Meredith RF; Partridge EE; Alvarez RD; Khazaeli MB; Plott G; Russell CD; Wheeler RH; Liu T; Grizzle WE; Schlom J; LoBuglio AF
J Nucl Med; 1996 Sep; 37(9):1491-6. PubMed ID: 8790200
[TBL] [Abstract][Full Text] [Related]
12. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide.
Janssen ML; Pels W; Massuger LF; Oyen WJ; Boonstra H; Corstens FH; Boerman OC
Int J Gynecol Cancer; 2003; 13(5):607-13. PubMed ID: 14675343
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
Cancer Biother Radiopharm; 2014 Oct; 29(8):323-9. PubMed ID: 25226447
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
Forero A; Meredith RF; Khazaeli MB; Shen S; Grizzle WE; Carey D; Busby E; LoBuglio AF; Robert F
Cancer Biother Radiopharm; 2005 Oct; 20(5):467-78. PubMed ID: 16248762
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal α-Emitting Radioimmunotherapy with
Hallqvist A; Bergmark K; Bäck T; Andersson H; Dahm-Kähler P; Johansson M; Lindegren S; Jensen H; Jacobsson L; Hultborn R; Palm S; Albertsson P
J Nucl Med; 2019 Aug; 60(8):1073-1079. PubMed ID: 30683761
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
Alvarez RD; Partridge EE; Khazaeli MB; Plott G; Austin M; Kilgore L; Russell CD; Liu T; Grizzle WE; Schlom J; LoBuglio AF; Meredith RF
Gynecol Oncol; 1997 Apr; 65(1):94-101. PubMed ID: 9103398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
